Close this search box.
Close this search box.

Boyds bolsters regulatory affairs team with key appointment

We are delighted to announce the appointment of experienced regulatory affairs professional and cell and gene therapy expert Dr Patrick Ginty.

With 17 years’ R&D and regulatory affairs experience in regenerative medicine and cell and gene therapy products, Patrick joins Boyds as Senior Director of Regulatory Affairs.

Most recently, Patrick was Head of Regulatory Affairs at AviadoBio, a biotechnology company developing gene therapies for neurodegenerative diseases. Prior to this, he was Head of Gene Therapy Regulatory Affairs at Handl Therapeutics (a fully owned subsidiary of UCB), and before this, Head of Regulatory Affairs at the Cell and Gene Therapy Catapult.

Patrick has a PhD in Tissue Engineering and Drug Delivery from the University of Nottingham, and completed additional post-PhD studies in Regulatory Affairs at San Diego State University, California.

At Boyds, Patrick will lead client projects, and provide strategic advice on complex regulatory matters, focusing on cell and gene therapy products. He will also help to grow the award-winning regulatory affairs team, as well as working closely with the various teams at Boyds to support the growth and development of the business.

Patrick says: “I am excited by the opportunity to work on a wide variety of products and technologies at all stages of development, within an organisation that has an excellent reputation for delivery and collaboration, particularly within cell and gene therapy and rare diseases. I am looking forward to bringing my therapeutic knowledge and experience of working with more than 50 cell and gene therapy products, as well as my collaborative and cross-functional approach to solving problems, to support the growth and development of both clients and the Boyds team.”

Dr Julie Warner, Vice President of Regulatory Affairs at Boyds, adds: “Patrick has extensive, proven experience in successfully translating complex and innovative therapies into the clinic and beyond, as both a technical expert and a senior leader. His varied therapeutic expertise will be a huge asset as we continue to support an increasing number of organisations, from biotechnology companies to academic spinouts, with regulatory matters, particularly in relation to advanced therapy medicinal products (ATMPs), and cell and gene therapies.”

Patrick previously served as Chair of the Alliance for Regenerative Medicine’s European Regulatory Affairs Committee, and was a member of the BioIndustry Association Regulatory Affairs Advisory Committee between 2017 and 2021. He also achieved certification for US Regulatory Affairs from the Regulatory Affairs Professionals Society (RAPS) in 2009.